Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Feb 25;9(2):e024424.
doi: 10.1136/bmjopen-2018-024424.

Surgical fasciectomy versus collagenase injection in treating recurrent Dupuytren disease: study protocol of a randomised controlled trial

Jesper Nordenskjöld  1   2 , Anna Lauritzson  1 , Markus Waldén  1 , Philippe Kopylov  1   2 , Isam Atroshi  1   2
Affiliations
Randomized Controlled Trial

Surgical fasciectomy versus collagenase injection in treating recurrent Dupuytren disease: study protocol of a randomised controlled trial

Jesper Nordenskjöld et al. BMJ Open. .

Abstract

Introduction: There is no definitive cure for Dupuytren disease (DD), and recurrence of finger contractures after treatment is common. Surgical fasciectomy is considered the standard treatment method for recurrence, although associated with a high incidence of complications. Collagenase injection, a non-surgical treatment option, has been shown to be a safe and effective method; however, most studies regarding collagenase have involved first-time treatment. Collagenase efficacy in patients with recurrent DD beyond the immediate effect has not yet been determined. The aim of our study is to compare surgical fasciectomy and collagenase injection in treating recurrent DD.

Methods and analysis: The study is a single-centre randomised controlled trial. Inclusion criteria are recurrence of DD in one or more fingers after previous treatment with fasciectomy or collagenase injection, a passive extension deficit ≥30° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint, and a palpable cord causing the recurrent contracture. A total of 56 patients will be randomised to either surgical fasciectomy or collagenase injection. A hand therapist blinded to patients' group allocation will measure range of motion at baseline, 3 months, 12 months, 24 months and 60 months. The primary outcomes are the total active extension deficit (MCP plus PIP) at 3 months and the proportion of patients with contracture worsening ≥20° in the treated finger joint at 2 years compared with 3 months. The secondary outcomes include changes in total active motion, active and passive extension deficit from baseline up to 5 years, scores on patient-reported outcome measures, adverse events and costs of treatment.

Ethics and dissemination: Ethical approval has been obtained from the Regional Ethical Review Board, Lund University, Sweden(2017/623). The trial will be conducted according to the Helsinki Declaration of 1975, revised in 2000. The results of the trial will be disseminated as published articles in peer-reviewed journals.

Trial registration: NCT03406338; Pre-results.

Keywords: dupuytren’s contracture; hand surgery; rct.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flowchart of the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lanting R, van den Heuvel ER, Westerink B, et al. . Prevalence of Dupuytren disease in the Netherlands. Plast Reconstr Surg 2013;132:394–403. 10.1097/PRS.0b013e3182958a33 - DOI - PubMed
    1. Degreef I, De Smet L. A high prevalence of Dupuytren’s disease in Flanders. Acta Orthop Belg 2010;76:316–20. - PubMed
    1. Gudmundsson KG, Arngrímsson R, Sigfússon N, et al. . Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik study. J Clin Epidemiol 2000;53:291–6. - PubMed
    1. Dibenedetti DB, Nguyen D, Zografos L, et al. . Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand 2011;6:149–58. 10.1007/s11552-010-9306-4 - DOI - PMC - PubMed
    1. Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand 2009;4:256–69. 10.1007/s11552-008-9160-9 - DOI - PMC - PubMed

Publication types

Associated data